Anika Therapeutics, Inc. (ANIK)
NASDAQ: ANIK · Real-Time Price · USD
17.18
+0.14 (0.82%)
Nov 20, 2024, 4:00 PM EST - Market closed
Anika Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 164.17 | 166.66 | 156.24 | 147.79 | 130.46 | 114.61 | Upgrade
|
| Revenue Growth (YoY) | 0.52% | 6.67% | 5.71% | 13.29% | 13.83% | 8.58% | Upgrade
|
| Cost of Revenue | 83.93 | 62.83 | 59.46 | 58.39 | 61.43 | 28.75 | Upgrade
|
| Gross Profit | 80.23 | 103.84 | 96.78 | 89.41 | 69.03 | 85.86 | Upgrade
|
| Selling, General & Admin | 67.78 | 82.85 | 84.79 | 74.1 | 56.74 | 34.56 | Upgrade
|
| Research & Development | 30.39 | 32.69 | 28.18 | 27.33 | 22.02 | 16.67 | Upgrade
|
| Operating Expenses | 98.17 | 115.54 | 112.98 | 101.42 | 78.76 | 51.23 | Upgrade
|
| Operating Income | -17.94 | -11.7 | -16.2 | -12.02 | -9.73 | 34.64 | Upgrade
|
| Interest Expense | - | - | - | -0.19 | -0.3 | - | Upgrade
|
| Interest & Investment Income | 2.17 | 2.31 | 0.65 | - | - | 1.87 | Upgrade
|
| EBT Excluding Unusual Items | -15.77 | -9.39 | -15.55 | -12.2 | -10.03 | 36.51 | Upgrade
|
| Merger & Restructuring Charges | -0.47 | -0.75 | -3.2 | -6.47 | -4.1 | - | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -42.52 | - | Upgrade
|
| Asset Writedown | -65.29 | -62.19 | - | - | -2.44 | -0.39 | Upgrade
|
| Other Unusual Items | -13 | -13 | - | 21.1 | 30.47 | - | Upgrade
|
| Pretax Income | -94.53 | -85.33 | -18.75 | 2.43 | -28.62 | 36.12 | Upgrade
|
| Income Tax Expense | 2.99 | -2.66 | -3.89 | -1.71 | -4.64 | 8.93 | Upgrade
|
| Net Income | -97.52 | -82.67 | -14.86 | 4.13 | -23.98 | 27.19 | Upgrade
|
| Net Income to Common | -97.52 | -82.67 | -14.86 | 4.13 | -23.98 | 27.19 | Upgrade
|
| Net Income Growth | - | - | - | - | - | 45.25% | Upgrade
|
| Shares Outstanding (Basic) | 15 | 15 | 15 | 14 | 14 | 14 | Upgrade
|
| Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 14 | 14 | Upgrade
|
| Shares Change (YoY) | 0.61% | 0.65% | -0.50% | 2.90% | -1.06% | -2.14% | Upgrade
|
| EPS (Basic) | -6.62 | -5.64 | -1.02 | 0.29 | -1.69 | 1.93 | Upgrade
|
| EPS (Diluted) | -6.62 | -5.64 | -1.02 | 0.28 | -1.69 | 1.89 | Upgrade
|
| EPS Growth | - | - | - | - | - | 48.82% | Upgrade
|
| Free Cash Flow | -0.81 | -7.22 | -3.08 | 3.25 | 11.44 | 34.18 | Upgrade
|
| Free Cash Flow Per Share | -0.05 | -0.49 | -0.21 | 0.22 | 0.80 | 2.38 | Upgrade
|
| Gross Margin | 48.87% | 62.30% | 61.94% | 60.49% | 52.91% | 74.92% | Upgrade
|
| Operating Margin | -10.93% | -7.02% | -10.37% | -8.13% | -7.46% | 30.22% | Upgrade
|
| Profit Margin | -59.40% | -49.60% | -9.51% | 2.80% | -18.38% | 23.73% | Upgrade
|
| Free Cash Flow Margin | -0.49% | -4.33% | -1.97% | 2.20% | 8.77% | 29.82% | Upgrade
|
| EBITDA | -8.05 | 2.52 | -1.71 | 2.3 | 3.74 | 40.63 | Upgrade
|
| EBITDA Margin | -4.91% | 1.51% | -1.10% | 1.56% | 2.86% | 35.45% | Upgrade
|
| D&A For EBITDA | 9.88 | 14.22 | 14.49 | 14.32 | 13.46 | 5.99 | Upgrade
|
| EBIT | -17.94 | -11.7 | -16.2 | -12.02 | -9.73 | 34.64 | Upgrade
|
| EBIT Margin | -10.93% | -7.02% | -10.37% | -8.13% | -7.46% | 30.22% | Upgrade
|
| Effective Tax Rate | - | - | - | - | - | 24.72% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.